Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2023-11-20T16:34:42Z | - |
dc.date.available | 2023-11-20T16:34:42Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2927-9270 | * |
dc.identifier.other | OAK-33929 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/266511 | - |
dc.description.abstract | INTRODUCTION:This prospective study aimed to investigate the efficacy and safety of preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF) for HBsAg-positive patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.METHODS:We enrolled 73 patients from 20 institutions. The primary end point was the absolute risk of hepatitis B virus (HBV)-related hepatitis during preemptive TDF therapy and for 24 weeks after withdrawal from TDF. Hepatitis was defined as a more than 3-fold increase in serum alanine aminotransferase from baseline or an alanine aminotransferase level of ≥100 U/L. HBV-related hepatitis was defined as hepatitis with an increase in serum HBV-DNA to >10 times that of the pre-exacerbation baseline or an absolute increase of ≥20,000 IU/mL compared with the baseline.RESULTS:No patient developed HBV reactivation or HBV-related hepatitis during preemptive antiviral therapy (until 48 weeks after completion of R-CHOP chemotherapy) with TDF. All adverse events were grade 1 or 2. HBV reactivation was reported in 17 (23.3%) patients. All HBV reactivation was developed at a median of 90 days after withdrawal from TDF (range, 37-214 days). Six (8.2%) patients developed HBV-related hepatitis at a median of 88 days after withdrawal from TDF (range, 37-183 days).DISCUSSION:Preemptive TDF therapy in HBsAg-positive patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy was safe and effective for preventing HBV-related hepatitis. However, a long-term maintenance strategy of preemptive TDF therapy should be recommended because of the relatively high rate of HBV-related hepatitis after withdrawal from TDF (ClinicalTrials.gov ID: NCT02354846). © 2023 Wolters Kluwer Health. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Wolters Kluwer Health | * |
dc.subject | antiviral therapy | * |
dc.subject | diffuse large B-cell lymphoma | * |
dc.subject | hepatitis B virus | * |
dc.subject | tenofovir disoproxil fumarate | * |
dc.title | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 118 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1373 | * |
dc.relation.lastpage | 1380 | * |
dc.relation.journaltitle | American Journal of Gastroenterology | * |
dc.identifier.doi | 10.14309/ajg.0000000000002185 | * |
dc.identifier.wosid | WOS:001048672500017 | * |
dc.identifier.scopusid | 2-s2.0-85166442279 | * |
dc.author.google | Kim D.Y. | * |
dc.author.google | Kim Y.R. | * |
dc.author.google | Suh C. | * |
dc.author.google | Yoon D.H. | * |
dc.author.google | Yang D.-H. | * |
dc.author.google | Park Y. | * |
dc.author.google | Eom H.S. | * |
dc.author.google | Lee J.-O. | * |
dc.author.google | Kwak J.-Y. | * |
dc.author.google | Kang H.J. | * |
dc.author.google | Hyun S.Y. | * |
dc.author.google | Jo J.-C. | * |
dc.author.google | Chang M.H. | * |
dc.author.google | Yoo K.H. | * |
dc.author.google | Lim S.-N. | * |
dc.author.google | Shin H.-J. | * |
dc.author.google | Kim W.S. | * |
dc.author.google | Kim I.-H. | * |
dc.author.google | Kim M.K. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Lee W.-S. | * |
dc.author.google | Mun Y.-C. | * |
dc.author.google | Kim J.S. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |